OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
85 hedge funds and large institutions have $156M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.
137% more call options, than puts
Call options by funds: $7.57M | Put options by funds: $3.19M
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
27% more capital invested
Capital invested by funds: $123M → $156M (+$33.3M)
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 86 → 85 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.9M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.98M |
| 3 |
Goldman Sachs
New York
|
+$2.49M |
| 4 |
Primecap Management
Pasadena,
California
|
+$930K |
| 5 |
CC
Cannell & Co
New York
|
+$694K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.47M |
| 2 |
Millennium Management
New York
|
-$754K |
| 3 |
First Eagle Investment Management
New York
|
-$623K |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$527K |
| 5 |
Morgan Stanley
New York
|
-$493K |
OMED Hedge Fund Activity: Q1 2017 in Review
85 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2017, worth a combined $156M — up 27% from $123M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new OMED positions and 11 closed out — a net gain of 5 holders — while 28 added to existing stakes and 25 trimmed.
The largest buyer was BlackRock, adding an estimated $14.9M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $1.47M sold.
- 85 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2017, down from 86 in Q4 2016.
- Funds reported $156M of OncoMed Pharmaceuticals, Inc. stock for Q1 2017, up 27% quarter-over-quarter.
- 16 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2017 and 11 closed out, a net change of +5 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $14.9M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2017 was Eventide Asset Management, an estimated $1.47M sold.
Based on aggregated 13F filings for Q1 2017.